Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19754779 | 0.81 | MAP3K12 (0.44) | HRH4MAP3K12 | |
| SCHEMBL8737264 | 0.78 | HDAC4 (0.38) | ALDH1A1PDE10AEGFR | |
| SCHEMBL15031757 | 0.78 | PGK1 (0.34) | PDE10A | |
| SCHEMBL17244888 | 0.76 | SCN9A (0.40) | HRH4ALDH1A1CACNA1H | |
| SCHEMBL29177457 | 0.75 | MBOAT4 (0.33) | HRH4PDE2AMAP3K12PDE10A | |
| SCHEMBL10141677 | 0.75 | ACHE (0.34) | — | |
| SCHEMBL17517152 | 0.73 | RXRA (0.34) | — | |
| SCHEMBL17973862 | 0.72 | PDE2A (0.35) | HRH4PDE2AALDH1A1CACNA1H | |
| SCHEMBL26739748 | 0.72 | ALPL (0.35) | KCNK3KCNK9PDE10AEGFR | |
| SCHEMBL22242846 | 0.72 | PDE2A (0.36) | HRH4PDE2AALDH1A1KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466171-B2 | Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20100256180-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256180-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NR5A1, AR, ESRRA | HRH4 420/4885PDE2A 1996/4885ALDH1A1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.